HR and breast cancer: In a 2019 report, HAS evaluated the clinical utility of GS in patients with HR+, HER2−, early BC in France and concluded that, due to limited effectiveness data available, there was no direct evidence for the clinical utility of the Oncotype DX® test when added to SoC (54).